权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery Disease

从基因座到功能：ZEB2 在人类冠状动脉疾病风险中的作用

基本信息

批准号：
10241961
负责人：
Paul Po Sheng cheng
金额：
$ 16.65万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-20 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10241961
关键词：
ATAC-seq Advisory Committees Affect Animal Model Arterial Fatty Streak Atherosclerosis Base Pairing Binding Biological Assay Biological Process Biology Cardiovascular Diseases Cause of Death Cell model Cell physiology Cells ChIP-seq Chromatin Remodeling Factor Chromosome 2 Clonality Clustered Regularly Interspaced Short Palindromic Repeats Code Computational Biology Coronary Arteriosclerosis Coronary artery Data Development Enhancers Epigenetic Process Epithelial Excision Funding Gene Expression Profiling Genes Genetic Genetic Epistasis Genetic Research Genetic Risk Genetic Transcription Genetic study Genome Genomic Segment Goals Heart Diseases Human Human Genetics In Vitro Individual K-Series Research Career Programs Lead Lesion Link Luciferases MADH3 gene Malignant Neoplasms Mediating Mentors Mesenchymal Modeling Molecular Movement Mus Myocardial Infarction Persons Phenotype Physicians Play Principal Investigator Proteins Regulatory Element Research Personnel Resolution Risk Role Rupture Scientist Signal Pathway Single Nucleotide Polymorphism Smad Proteins Smooth Muscle Myocytes Stimulus Testing Training Transcription Repressor Transcriptional Regulation Translating Universities Untranslated RNA Work atherosclerosis risk base career causal variant chromosome conformation capture design disorder risk epigenetic profiling epigenome editing epigenomics genetic risk factor genome editing genome wide association study genome-wide genomic locus in vivo in vivo Model insight multiple omics novel novel therapeutics prevent programs promoter research study response risk variant screening skills tool transcription factor transcriptome sequencing transcriptomics tumorigenesis

项目摘要

ABSTRACT Coronary artery disease (CAD) remains the leading cause of death in the U.S. and worldwide. Identifying genetic risk factors and uncovering the underlying biological processes will lead to the development of much needed new avenues for therapies. Decades of genetics research, especially genome wide association studies (GWAS), have led to the discovery of numerous genetic loci associated with an increased risk for CAD. However, the majority of these loci lie in non-protein-coding regions. Efforts are needed to identify causal genes associated with these loci and the underlying cellular processes and signaling pathways. Recent advances in epigenomic and transcriptomic profiling at unprecedented depth and resolution, along with targeted genome/epigenome editing provide new opportunities to identify specific genes and cellular mechanisms in CAD. This K08 career development award is designed to launch the principal investigator’s career as an independent physician scientist that utilizes complementary computational and molecular approaches to discover the mechanisms that underlies human genetic risk to cardiovascular disease and translates these findings into treatment. The principal investigator ‘s Mentor (Thomas Quertermous) is a world leader in mechanistic studies of genetic risk of atherosclerosis. The proposed training is further supplemented by an advisory committee of leaders in computational biology, genetics, and single-cell multi-omic analysis, including Michael Snyder, Erik Ingelsson, William Greenleef, and Siddhartha Jaiswal, along with formal didactic courses at Stanford University and Cold Spring Harbor. Funded by an F32, the principle investigator used a combination of in vitro and in vivo models of atherosclerosis and linked the non-coding CAD risk loci at 2q22 to ZEB2, a transcriptional repressor with a critical role in cell-state transitions. ZEB2 appears to be specifically up-regulated in phenotypically modulated smooth muscle cells (SMC) in atherosclerotic lesions, and modulates their cell-fate decisions. The proposed study will: (1) identify the causal regulatory element(s) responsible for the CAD-Risk-associated region at 2q22; (2) reveal the molecular mechanisms by which ZEB2 affects phenotypic modulation of SMC; (3) determine the cellular mechanism by which perturbation of smooth muscle cell Zeb2 expression modulates atherosclerotic lesions in vivo. The result of this study will elucidate new regulatory mechanisms that modulate atherosclerosis biology. Additionally, the principle investigator will gain the training needed to transition into an independent physician scientist focusing on translating genetic findings of human cardiovascular disease into specific mechanisms and novel therapies.

摘要